Completed PHASE2 INTERVENTIONAL 1-arm NCT00651833

Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer

An Open-Label, Non-Randomized, Multicenter, Three-Stage, Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy for Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIB/Stage IV)

Sponsor: Quintiles, Inc.

Conditions Advanced Non-Small Cell Lung Cancer

Interventions S-1

Updated 8 times since 2017 Last updated: Aug 30, 2024 Started: Feb 28, 2005 Primary completion: Oct 31, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00651833, this PHASE2 trial focuses on Advanced Non-Small Cell Lung Cancer and remains completed. Sponsored by Quintiles, Inc., it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE2
Sep 2024 — Oct 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Apr 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Apr 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Quintiles, Inc.
Taiho Oncology, Inc.
United BioSource, LLC

Data source: Taiho Oncology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.